China May Ease Data Transfer Rules But Regulatory Ambiguity Remains
New Approach To 'Important Data'
Executive Summary
China's latest proposed rules governing the overseas transfer of personal data may allow pharma, biotech and digital health companies to avoid regulatory security reviews and formal standard contracts, as well as personal information protection certification, but key definitions of “important data” and “negative list” items remain to be clarified.